Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Jiaqi Sheng *Department of Hematology, the First Affiliated Hospital of Soochow University & State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Soochow University, Suzhou, 215000, China.
Depei Wu *Department of Hematology, the First Affiliated Hospital of Soochow University & State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Soochow University, Suzhou, 215000, China.ORCID 0000-0002-6312-3863
Jingzhe Shang *State Key Laboratory of Common Mechanism Research for Major Diseases, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, China.
Xiaodan Fu *Department of Hematology, the First Affiliated Hospital of Soochow University & State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Soochow University, Suzhou, 215000, China.
He GaoInstitutes of Biology and Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, 215123, China.
Jianjie RongDepartment of Vascular Surgery, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, 215000, China.
Jun WangInstitutes of Biology and Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, 215123, China. jwang79@suda.edu.cn.ORCID 0000-0002-4458-3741
Jiancheng HuLaboratory of Molecular Mechanism & Targeted Therapy, National Cancer Center Singapore, Singapore General Hospital, Duke-NUS Medical School, Singapore, 168583, Singapore. jiancheng.hu@duke-nus.edu.sg.ORCID 0000-0003-1615-0030
Xiaofei QiDepartment of Hematology, the First Affiliated Hospital of Soochow University & State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Soochow University, Suzhou, 215000, China. qixf-sz@hotmail.com.ORCID 0000-0003-0879-7344
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Efficacy of radiation therapy is compromised by hematopoietic and immune impairments, with elusive underlying causes. This study aimed to elucidate Usp11's role in radiation-induced injuries and uncover related mechanisms. Utilized ARS mouse model to observe survival rates of Usp11
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Usp11 maintained the survival of marginal zone B cells under ionizing radiation by deubiquitinating DLL1 and JAG2. · full record | OpenQuestion